PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Lonza Group's PE Ratio without NRI is 40.19. Lonza Group's 5-Year EBITDA growth rate is 4.90%. Therefore, Lonza Group's PEG Ratio for today is 8.20.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Lonza Group's PEG Ratio or its related term are showing as below:
LZAGY'
s PEG Ratio Range Over the Past 10 Years
Min: 1.62 Med: 4.58 Max: 14.61
Current: 8.2
During the past 13 years, Lonza Group's highest PEG Ratio was 14.61. The lowest was 1.62. And the median was 4.58.
LZAGY's PEG Ratio is ranked worse than 89.66% of 58
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.555
vs LZAGY: 8.20
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Lonza Group PEG Ratio Historical Data
The historical data trend for Lonza Group's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Lonza Group's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group's PEG Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Lonza Group's PEG Ratio falls into.
Lonza Group PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
Lonza Group's PEG Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Lonza Group (OTCPK:LZAGY) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Lonza Group PEG Ratio Related Terms
Thank you for viewing the detailed overview of Lonza Group's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LZAGY has been successfully added to your 